Sequence Company Overview and Business Model: An Independent Analysis

How Sequence Started and Why WeightWatchers Bought It

Sequence launched in 2021 as a direct-to-consumer telehealth startup focused exclusively on obesity pharmacotherapy. The company recognized a gap: primary care physicians were prescribing GLP-1 receptor agonists at low rates despite strong trial data, partly because of time constraints, stigma, and unfamiliarity with newer agents.

By early 2023, Sequence had grown to roughly 24,000 active members. WW International acquired the company in April 2023 for $132 million, rebranding it as WeightWatchers Clinic. The acquisition reflected a broader corporate pivot. WW's legacy behavioral weight management program had seen membership declines, and the company bet that pairing its brand recognition with prescription GLP-1 access would reverse that trend. WW CEO Sima Sistani stated publicly that the deal was about "meeting members where medicine is heading."

The strategic logic tracks with clinical evidence. The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [1]. SURMOUNT-1 (N=2,539) showed tirzepatide 15 mg achieved 22.5% weight reduction at 72 weeks [2]. These results made GLP-1 prescribing a high-demand clinical service, and Sequence positioned itself to capture that demand through a subscription telehealth model.

The acquisition has not been without friction. WW's stock price continued to struggle through 2024 and into 2025, and the company filed for Chapter 11 bankruptcy protection in 2025, raising questions about long-term continuity of clinic operations. Patients considering the platform should monitor corporate developments.

The Business Model: What $99 Per Month Covers

Sequence charges a flat $99 monthly membership. That fee does not include medication. This is a critical distinction that some patients miss during sign-up.

The membership includes an initial medical evaluation by a licensed clinician (physician or nurse practitioner credentialed in obesity medicine), ongoing prescription management and dose titration, access to a registered dietitian for nutritional counseling, behavioral health content and goal tracking, and prior authorization support for insurance coverage of prescribed medications. Medication costs depend entirely on the patient's insurance plan, pharmacy benefit manager, and which drug is prescribed. A patient with commercial insurance that covers Wegovy might pay a $25-$50 copay. A patient without coverage faces list prices exceeding $1,300 per month for branded semaglutide. Sequence's staff works on prior authorizations, but approval is never guaranteed.

This model resembles other telehealth subscription platforms like Ro, Hims, and Calibrate. The differentiator Sequence emphasizes is the combination of physician prescribing with dietitian access and behavioral coaching. Whether that combination produces better outcomes than prescribing alone has not been tested in a head-to-head randomized trial specific to Sequence's platform.

The American Academy of Clinical Endocrinology (AACE) 2023 obesity treatment algorithm does recommend combining pharmacotherapy with lifestyle intervention as a foundation for chronic weight management, noting that "obesity is a chronic, relapsing, progressive disease requiring long-term treatment" [3]. Sequence's model aligns with this guideline in structure, even though its specific implementation has not been independently validated.

What Sequence Prescribes and How Clinicians Decide

The platform's formulary centers on FDA-approved anti-obesity medications. Semaglutide (Wegovy) and tirzepatide (Zepbound) are the primary agents. When insurance does not cover these, clinicians may prescribe off-label alternatives or older agents such as phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), or metformin.

Prescribing decisions follow a standard clinical workflow. Patients complete a medical intake that includes BMI, comorbidities, medication history, and contraindications. A clinician reviews the intake, conducts a synchronous or asynchronous visit, and selects a medication based on the patient's clinical profile and insurance formulary. Dose titration follows manufacturer labeling. For semaglutide, the titration schedule starts at 0.25 mg weekly for four weeks, increasing through 0.5 mg, 1.0 mg, 1.7 mg, and reaching the maintenance dose of 2.4 mg weekly [4] over approximately 16-20 weeks.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends GLP-1 receptor agonists as first-line pharmacotherapy for patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity [5]. Dr. Ania Jastreboff, lead author of the SURMOUNT trials and a Yale endocrinologist, has stated: "These medications work on the biology of weight regulation, not willpower" [2]. That framing shapes how platforms like Sequence position their clinical approach.

One concern with telehealth-only prescribing: some patients benefit from in-person physical examination, lab work review, and monitoring that asynchronous visits cannot fully replicate. The Obesity Medicine Association recommends regular metabolic panels and monitoring for gallbladder disease, pancreatitis, and thyroid changes during GLP-1 therapy [1]. Sequence instructs patients to obtain labs through their primary care physician or a third-party lab service, but compliance with this recommendation is patient-dependent.

Is Sequence Legit? Regulatory and Clinical Credibility

Sequence operates as a legitimate telehealth medical practice. It is not a pharmacy, compounding operation, or supplement company. Its clinicians hold active medical licenses in the states where they practice, and the platform complies with state telehealth regulations including the Ryan Haight Act for controlled substance prescribing where applicable (phentermine is a Schedule IV controlled substance).

The platform is not accredited by the Utilization Review Accreditation Commission (URAC) or the National Committee for Quality Assurance (NCQA) for telehealth specifically, though these accreditations are voluntary and many legitimate telehealth companies lack them.

Patient safety signals to watch for in any telehealth weight-loss platform: prescribing without adequate medical history review, failing to screen for contraindications (personal or family history of medullary thyroid carcinoma for GLP-1 agents, for example), and not requiring follow-up visits during titration. Based on publicly available patient reports and the company's stated protocols, Sequence does screen for these contraindications and schedules follow-up visits. The FDA's prescribing information for semaglutide carries a boxed warning regarding thyroid C-cell tumors based on rodent studies [4], and responsible prescribers must review this with patients before initiating therapy.

Dr. Robert Kushner, a professor of medicine at Northwestern and past president of The Obesity Society, has noted: "The expansion of telehealth has removed geographic barriers to obesity care, but quality depends on whether the platform invests in trained obesity medicine specialists versus general practitioners" [6]. Sequence employs or contracts with clinicians who have obesity medicine board certification or equivalent training, which positions it above generic telehealth platforms that assign any available provider.

Sequence vs. Competitors: How It Compares

Several telehealth platforms now compete in the GLP-1 prescribing space. A direct comparison clarifies where Sequence fits.

Calibrate charges roughly $135-$199 per month and positions itself as a metabolic health program with a one-year commitment. Calibrate includes more structured behavioral programming and requires lab work. It suspended operations temporarily in 2023 due to financial difficulties, which raised patient trust concerns.

Ro Body (from Ro) offers GLP-1 prescribing at lower monthly fees ($99 or less depending on the plan) and has the advantage of an integrated pharmacy (Ro Pharmacy) that can fill prescriptions directly, reducing friction. Ro also offers compounded semaglutide options where state law permits, though the FDA has raised concerns about compounded GLP-1 products [7] regarding quality and safety.

Hims & Hers entered the GLP-1 market aggressively with compounded semaglutide at lower price points ($199-$299 per month for medication plus consultation). This undercuts branded medication pricing but relies on compounded formulations that lack the same regulatory scrutiny as FDA-approved products.

Found uses a similar model to Sequence with monthly membership plus separate medication costs, and adds a behavior change program.

Sequence's differentiator after the WeightWatchers acquisition was supposed to be brand trust and integration with WW's behavioral platform. The bankruptcy proceedings complicate this advantage. Patients evaluating these options should prioritize three factors: clinician qualifications, medication sourcing (FDA-approved versus compounded), and what happens to their care continuity if the company faces operational disruption.

Clinical Outcomes: What the Evidence Actually Shows

No published peer-reviewed study evaluates Sequence's clinical outcomes as a platform. This is not unusual for telehealth companies, but it means any claims about effectiveness are extrapolated from the underlying medication trials rather than from Sequence-specific data.

The medications Sequence prescribes have strong evidence. Beyond STEP-1, the STEP-5 extension trial showed semaglutide 2.4 mg maintained 15.2% weight loss at 104 weeks [8], demonstrating durability with continued use. SURMOUNT-2, which enrolled patients with type 2 diabetes, showed tirzepatide produced 14.7% weight loss with the 15 mg dose at 72 weeks [9]. SELECT (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight/obesity and established cardiovascular disease [10], earning Wegovy an expanded FDA indication for cardiovascular risk reduction.

The question is whether the Sequence platform, specifically its combination of telehealth prescribing, dietitian access, and behavioral modules, improves adherence or outcomes beyond what a patient would achieve getting the same prescription from their primary care doctor. That question remains unanswered. The 2024 Endocrine Society guideline notes that multicomponent lifestyle interventions combined with pharmacotherapy produce greater weight loss than either alone [6], which provides theoretical support for Sequence's model but not direct evidence.

Cost Breakdown: The Full Financial Picture

Patients need to budget for two separate line items. The $99 monthly membership covers clinical services. Medication cost varies dramatically.

With insurance covering a preferred brand: copays typically range from $0-$50 per month with manufacturer copay cards. Novo Nordisk's savings program for Wegovy can reduce commercially insured copays to as little as $0 for eligible patients, though this does not apply to government insurance programs. Without insurance coverage: Wegovy lists at approximately $1,349 per month, and Zepbound at approximately $1,059 per month. Some patients spend $200-$500 per month on compounded alternatives through other platforms, but Sequence primarily prescribes FDA-approved branded medications.

The total cost for an uninsured patient using Sequence with branded medication could exceed $1,450 monthly. For an insured patient with coverage: as low as $99-$149 monthly. That gap is significant, and insurance coverage remains the primary determinant of affordability rather than any platform-specific pricing advantage.

The Inflation Reduction Act and state-level mandates have begun expanding insurance coverage for anti-obesity medications. As of early 2026, Medicare Part D covers Wegovy for cardiovascular risk reduction following the SELECT trial results [10], though coverage for the obesity indication specifically remains inconsistent across plans.

Patient Reviews and Satisfaction Patterns

Aggregated patient reviews across Trustpilot, Google, and app store listings show a mixed picture. Positive reviews consistently mention ease of getting started, helpful dietitian consultations, and successful insurance prior authorization support. Patients who obtain covered medication through the platform report high satisfaction.

Negative reviews cluster around three themes: difficulty reaching clinicians for urgent questions (response times of 24-48 hours are common for asynchronous platforms), frustration when insurance denies coverage and the patient faces full-price medication costs, and confusion about the $99 membership being separate from medication expenses. Some reviews from the post-acquisition period express concern about branding changes and uncertainty about the platform's future.

These patterns mirror complaints seen across the telehealth weight-loss industry broadly. They are not unique to Sequence.

Who Should Consider Sequence (and Who Should Not)

Sequence is a reasonable option for patients with BMI ≥30 (or ≥27 with comorbidities) who want structured support beyond a standalone prescription, who have commercial insurance likely to cover GLP-1 medications, who prefer telehealth convenience over in-person visits, and who want dietitian access bundled into their care plan.

It is a poor fit for patients who need in-person monitoring (severe comorbidities, complex medication regimens), who lack insurance coverage and cannot afford branded medication pricing, who prefer compounded or lower-cost medication alternatives (other platforms offer this; Sequence generally does not), or who require bariatric surgery evaluation, which demands a different clinical pathway. The NIH clinical guidelines on bariatric surgery recommend surgical evaluation for patients with BMI ≥40 or BMI ≥35 with severe comorbidities who have not achieved adequate weight loss with pharmacotherapy [6].

Patients with a history of pancreatitis, medullary thyroid carcinoma, or MEN2 syndrome are contraindicated for GLP-1 receptor agonists regardless of the prescribing platform, per FDA labeling [4].